KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Inventory Average: 2009-2025

Historic Inventory Average for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $183.7 million.

  • Halozyme Therapeutics' Inventory Average rose 26.34% to $183.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.7 million, marking a year-over-year increase of 26.34%. This contributed to the annual value of $134.7 million for FY2024, which is 18.33% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Inventory Average stood at $183.7 million, which was up 6.04% from $173.2 million recorded in Q2 2025.
  • Halozyme Therapeutics' Inventory Average's 5-year high stood at $183.7 million during Q3 2025, with a 5-year trough of $50.8 million in Q1 2022.
  • Its 3-year average for Inventory Average is $144.3 million, with a median of $145.4 million in 2024.
  • Per our database at Business Quant, Halozyme Therapeutics' Inventory Average decreased by 14.63% in 2022 and then skyrocketed by 104.24% in 2023.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Inventory Average stood at $54.9 million in 2021, then spiked by 85.10% to $101.7 million in 2022, then increased by 26.12% to $128.3 million in 2023, then rose by 6.53% to $136.6 million in 2024, then increased by 26.34% to $183.7 million in 2025.
  • Its Inventory Average was $183.7 million in Q3 2025, compared to $173.2 million in Q2 2025 and $153.4 million in Q1 2025.